Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13827599 | 0.87 | LRRK2 (0.41) | RIPK1LRRK2CCNA2CDK2CCNA1 | |
| SCHEMBL17029319 | 0.83 | LRRK2 (0.43) | LRRK2CCNA2CDK2CCNA1EP300 | |
| SCHEMBL13827779 | 0.80 | LRRK2 (0.42) | LRRK2CCNA2CDK2CCNA1EP300 | |
| SCHEMBL13819913 | 0.79 | NUDT1 (0.43) | NUDT1 | |
| SCHEMBL18888380 | 0.76 | LRRK2 (0.45) | LRRK2CCNA2CDK2CCNA1FFAR4 | |
| SCHEMBL19510667 | 0.74 | LRRK2 (0.43) | LRRK2CCNA2CDK2CCNA1FFAR4 | |
| SCHEMBL28019841 | 0.73 | KCNH2 (0.39) | RIPK1LRRK2 | |
| SCHEMBL15677581 | 0.73 | LRRK2 (0.41) | LRRK2CCNA2CDK2CCNA1EP300 | |
| SCHEMBL22834474 | 0.72 | NUDT1 (0.53) | LRRK2NUDT1CCNA2CDK2CCNA1 | |
| SCHEMBL28020350 | 0.71 | PDE2A (0.51) | LRRK2NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9403782-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150329558-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-11-19 | — | — | US | disclosed |
| US-9115096-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | RIPK1 2773/4885LRRK2 1834/4885NUDT1 1865/4885 |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | RIPK1 2773/4885LRRK2 1834/4885NUDT1 1865/4885 |
| US-20150329558-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | RIPK1 2773/4885LRRK2 1834/4885NUDT1 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.